Jennifer R. Brown, M.D. Ph.D.
Assistant Professor, Department of Medicine, Harvard Medical School
Assistant Professor of Medicine, Lymphoma Program, Dana-Farber Cancer Institute
Contact Info
Jennifer Brown
Dana-Farber Cancer Institute
44 Binney Street
Boston, MA, 02115
Mailstop: D1B18
Phone: 617-632-4894
Fax: 617-582-7909
jbrown2@partners.org
Administrative Assistant
Lymphoma Program
Dana-Farber Cancer Institute
44 Binney Street
Boston, MA, 02115
Phone: 617-632-4894
Fax: 617-582-7909
shalika_smith@dfci.harvard.edu
Dana-Farber Cancer Institute
44 Binney Street
Boston, MA, 02115
Mailstop: D1B18
Phone: 617-632-4894
Fax: 617-582-7909
jbrown2@partners.org
Assistant
Shalika SmithAdministrative Assistant
Lymphoma Program
Dana-Farber Cancer Institute
44 Binney Street
Boston, MA, 02115
Phone: 617-632-4894
Fax: 617-582-7909
shalika_smith@dfci.harvard.edu
DF/HCC Program Affiliation
Lymphoma and MyelomaResearch Abstract
My research interests have two principal goals: the development of a clinical and translational research program in CLL at Dana-Farber Cancer Institute, and understanding and characterizing the biology of familial lymphoproliferative disorders. My efforts to develop a CLL clinical research program at DFCI are starting to come to fruition. I have investigator-initiated trials which are funded, written and in the IRB process, for the initial therapy of CLL, second-line therapy of CLL, and more relapsed disease. In the area of translational science in CLL, I have created a CLL tissue bank and have provided CLL samples collaboratively to multiple DFHCC investigators. We are also screening a number of drugs that are in preclinical development for their ability to induce apoptosis in primary CLL cells in vitro. The other significant focus of my current efforts is the development of a tissue and data bank of familial lymphoma, which in the past two years has enrolled approximately 240 subjects. The eventual goal of this project is to characterize the unique biology of familial lymphoproliferative disorders and eventually to define the underlying genetic predisposition.Publications
- Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A.Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.J Clin Invest 2007 Jan;117(1):112-21.
17200714 - Brown JR, Kim HT, Li S, Stephans K, Fisher DC, Cutler C, Ho V, Lee SJ, Milford EL, Ritz J, Antin JH, Soiffer RJ, Gribben JG, Alyea EP.Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced
17084369 - Brown JR, Yeckes H, Friedberg JW, Neuberg D, Kim H, Nadler LM, Freedman AS.Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's ly
15753460 - Brown JR, Gaudet G, Friedberg JW, Neuberg D, Mauch P, Kutok JL, Takvorian T, Fisher DC, Gribben JG, Kim H, Nadler LM, Freedman AS.Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma.Leuk Lymphoma 2004 Feb;45(2):315-20.
15101717




